Windlas Biotech bags EU-GMP certificate; stock trades flat

25 May 2022 , 10:24 AM

Windlas Biotech Limited informed in its regulatory filing that it has now received the certificate of European Union Good Manufacturing Practices (EU-GMP) by the National Institute of Pharmacy and Nutrition, Hungary for the Plant-IV situated at Dehradun.

For this certification, the company had undergone an inspection between April 11 to April 13, 2022.

Mr. Hitesh Windlass, Managing Director of Windlas Biotech commented on this, “We are pleased to be honored with the EU-GMP certificate for our Plant-IV. The company received the GMP certificate from SAHPRA (South African Health Products Regulatory Authority) for the same plant in April 2022.

He further added, “These successive positive outcomes from the reputed regulatory authorities are evidence of the company’s core philosophy. We believe in adhering to the highest standards of quality, maintaining robust systems and strong execution capabilities. With the successful completion of these audits, the company could be able to expand its geographic presence in those respective markets.”

At around 10.39 AM, Windlas Biotech was trading at Rs221.50, down by 0.67% of Rs1.50, against its previous close of Rs223 on NSE. It opened at Rs226.15 and touched intraday high and low of Rs226.15 and Rs221 respectively so far.